CA 125 and the detection of recurrent ovarian cancer
Open Access
- 11 June 2010
- Vol. 116 (12), 2850-2853
- https://doi.org/10.1002/cncr.25203
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic massAmerican Journal of Obstetrics and Gynecology, 2010
- Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)The Lancet Oncology, 2009
- A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic massGynecologic Oncology, 2009
- Early Detection of Ovarian CancerBiomarkers in Medicine, 2008
- The associations between knowledge, CA125 preoccupation, and distress in women with epithelial ovarian cancerGynecologic Oncology, 2006
- Risk of Epithelial Ovarian Cancer Recurrence in Patients With Rising Serum CA-125 Levels Within the Normal RangeJournal of Clinical Oncology, 2005
- Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trialThe Lancet, 2003
- Defining progression of ovarian carcinoma during follow-up according to CA 125: A North Thames Ovary Group studyAnnals Of Oncology, 1996
- A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancerBJOG: An International Journal of Obstetrics and Gynaecology, 1990
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983